Tag:
XTL Biopharmaceuticals
Latest Headlines
Latest Headlines
XTL snags schizophrenia drug in exclusive licensing pact
XTL Biopharmaceuticals ( $XTLB ) has struck an interesting deal to land a badly-needed late-stage therapy for its pipeline. The company gained an exclusive license for all the technology on hand at
XTL Biopharma juggles buyout offers, delisting
The tiny developer XTL Biopharmaceuticals is juggling some merger offers at the same time Nasdaq says it intends to delist the company's floundering stock. XTL officials announced that they are
Tiny XTL cuts costs, jobs
New York-based XTL Biopharmaceuticals won't be able to recover from the failure of its diabetic neuropathic pain drug bicifadine . XLT announced today that it is laying off nine employees, or 75
XTL shares clobbered on lead drug trial failure
Shares of New York-based XTL Biopharmaceuticals were almost completely wiped out overnight after the developer announced that a mid-stage trial of its lead therapy failed to hit its primary endpoint.
